The drug for repletion of the lack of growth hormone has been approved in the United States
Управление по санитарному надзору за качеством пищевых продуктов и медикаментов США (FDA) одобрило препарат Ngenla (соматрогон) от компании Pfizer для лечения дефицита гормона роста у детей, разработанный совместно с OPKO Health....
Saved in:
Main Author: | article Editorial (Author) |
---|---|
Format: | Book |
Published: |
Union of pediatricians of Russia,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The world's first topical gene therapy drug for epidermolysis bullosa patients has been approved
by: article Editorial
Published: (2023) -
FDA Has Approved First Long-Acting Growth Hormone Preparation for Children
by: article Editorial
Published: (2021) -
Lack of efficacy of ergocalciferol repletion
by: Thomas Wasser, et al.
Published: (2012) -
The FDA has approved the first medical drug for Rett syndrome
by: article Editorial
Published: (2023) -
Two new indications for pembrolizumab have been approved in Russia
by: article Editorial
Published: (2020)